Optimization of Cyclosporin in Atopic Dermatitis Through Multiomic Predictive Models of Treatment Response

Inclusion Criteria: Cohort 1:

1. Subjects diagnosed with moderate-severe atopic dermatitis who are going to receivetreatment with cyclosporine.
2. Participants must be willing and able to provide written informed consent prior theinitiation of any study procedures.
3. For children, parent/legal guardian must provide written informed consent. If age >11years old, the minor must give assent.
4. Participant is willing and able to adhere to the procedures specified in thisprotocol. Cohort 2:
5. Subjects diagnosed with moderate-severe atopic dermatitis who are receiving or havereceived in the past treatment with cyclosporine.
6. Participants must be willing and able to provide written informed consent prior theinitiation of any study procedures.
7. For children, parent/legal guardian must provide written informed consent. If age >11years old, the minor must give assent.
8. Participant is willing and able to adhere to the procedures specified in thisprotocol.

Exclusion Criteria:

1. Subjects participating in a clinical trial in the last three months.
2. Any condition or situation precluding or interfering the compliance with the protocol.
3. Women of childbearing potential must have a negative urine pregnancy test at Screeningand Day 0.
4. Women of childbearing potential must commit not to become pregnant. They must bewilling to use highly effective contraceptive methods or have practiced sexualabstinence during the study. Highly effective contraceptive methods include oral,intravaginal, or transdermal combined (oestrogen and progestogen containing) hormonalcontraception associated with inhibition of ovulation; oral, injectable, orimplantable progestogen-only hormonal contraception associated with inhibition ofovulation; intrauterine device; intrauterine hormone-releasing system; bilateral tubalocclusion; vasectomised partner and sexual abstinence.